Q1: What non-sterile dosage forms can Eramol manufacture?
Eramol supports a full suite of non-sterile manufacturing including tablets, capsules, and oral liquids, covering both active and placebo formulations.
With a capacity of 40,000 tablets per hour and tablet sizes from 5 mm to 25 mm, Eramol is equipped for a wide range of clinical and early commercial projects.
All production is carried out under GMP oversight, with integrated QA, regulatory support, and QP governance for guaranteed quality.
Q2: Does Eramol provide blinding, over-encapsulation, and placebo-matching services?
Yes—Eramol offers over-encapsulation, blinding (visual, taste, smell), and placebo manufacturing to support comparator studies, randomised trials, and double-blind clinical designs.
These capabilities integrate seamlessly with packaging, labelling, QP release, storage, and distribution, enabling a single-vendor, end-to-end supply-chain approach that reduces timelines and improves trial quality.